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1. Introduction 
Ten cases of human prothrombin variants have 
been reported up to now. One of the last was pro- 
thrombin Metz [l] in a French family. The mother is 
heterozygous for the abnormal prothrombin and the 
father heterozygous for true hypoprothrombinemia. 
The 4 possible genetic combinations are realized 
among the 8 children. Three of them, presenting a 
mild bleeding tendency, are double heterozygotes for 
prothrombin Metz and the hypoprothrombinemia 
and therefore bear only the abnormal molecule. This 
case constitutes the third observation of such an asso- 
ciation [2,3]. 
At the present time 3 of the prothrombin variants 
have been fully purified and characterized. In the 
cases of prothrombin Barcelona [4-61 and prothrom- 
bin Madrid [7] the molecular defect has been shown 
to be a specific impairment of one of the two factor 
Xa-catalyzed cleavages, whereas in the case of pro- 
thrombin Quick [8] the abnormality lies in the throm- 
bin part of the molecule. 
Here we present the purification and partial charac- 
terization of prothrombin Metz. The purified material 
is indistinguishable from normal prothrombin by all 
the studied physicochemical criteria. However, activa- 
tion by factor Xa in purified system generates only 
amidolytic activity but no clotting activity. An abnor- 
mal cleavage pattern is observed which is different 
from those described for prothrombin Barcelona and 
prothrombin Madrid. 
A preliminary report of this study has been presented at the 
7th Int. Cong. Thrombosis and Haemostasis, July 1979, 
London [20] 
Elsevier/North-HoIland Biomedical Press 
2. Material and methods 
For comparison purposes, normal prothrombin 
and prothrombin Metz were purified in parallel, start- 
ing from small quantities of plasma (30-60 ml), using 
barium citrate adsorption/elution, ammonium sulfate 
precipitation [9] and DEAE-Sephadex chromatog- 
raphy [lo]. Prothrombin was assayed by double 
immunodiffusion [ 1 l] and quantitated by the Laurel1 
method [I 21 using specific anti-human prothrombin 
antibodies. 
Urea-SDS gel electrophoresis was performed 
according to [ 131 in 12.5% acrylamide with a 40/l 
acrylamide bisacrylamide ratio. Disc gel electropho- 
resis was carried out at pH 8.9 according to [ 14,l S] 
and at pH 7.2 and 5.5 according to [16]. 
The N-terminal residue was determined by dansyl- 
ation [ 171. 
Factor Xa was obtained from Sigma. Crude human 
brain cephalin was used as source of phospholipids. 
Activation of prothrombin was performed in Tris 
0.025 M, NaClO.15 M (pH 7.4). Thrombin activity 
was measured by clotting assay [ 181 and spectropho- 
tometrically using the synthetic substrates ?!&, and 
SW&ABI) P91. 
3. Results and discussion 
3.1. Purification and physicochemical charactenka- 
tion 
For the purification of prothrombin Metz, advan- 
tage has been taken of the existence in the family of 
3 siblings who, being double heterozygotes for pro- 
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Fig.1. Elution pattern of normal and abnormal prothrombins from DEAE-Sephadex. The column (1.5 X 30 cm) was eluted at a 
10 ml/h flowrate with a linear gradient of NaCl (0.05-0.5 M) in Tris-citrate buffer 0.05 M (pH 6_.5) (200/200 ml). Normal pro- 
thrombin (+--); prothrombin Barcelona (---); prothrombin Metz (- . - .). 
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Fig.2. Polyacrylamide gel electrophoresis of normal and abnormal prothrombins. (A) Urea-SDS gel electrophoresis. (B) Disc-gel 
electrophoresis at pH 8.9 (12% acrylamide, height 10 cm) performed during prolonged time (2 h at 2 mA/gel after the marker 
reached the end of the gel). 
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thrombin Metz and hypoprothrombinemia, have no 
normal prothrombin. Prothrombin Metz is totally 
adsorbed onto barium citrate, as shown by immuno- 
logical assay. The usual technique for p othrombin 
purification has therefore been used to isolate the 
abnormal molecule. One single symmetrical peak con- 
taining prothrombin isobtained from the DEAE- 
Sephadex column eluted at the same ionic strength as 
normal prothrombin (fig. 1). This result is in contrast 
with what is observed with Barcelona plasma where 
two peaks are obtained, aslightly delayed prothrom- 
bin Barcelona peak and a second one containing pro- 
thrombin crossreacting material. 
Pure material is obtained as shown by SDS-gel 
electrophoresis (fig.2A) which reveals a single band 
with the same mobility as normal prothrombin corre- 
sponding to mol. wt 72 000. As for normal prothrom- 
bin, alanine is the only N-terminal residue revealed by 
dansylation. No charge difference is found by gel elec- 
trophoresis n a native system neither at pH 8.9 (fig. 
2B) nor at pH 7.2 and 5.5. 
Prothrombin Metz therefore is indistinguishable 
from normal prothrombin by the studied physico- 
chemical criteria. In comparison prothrombin Barce- 
lona exhibits a more anionic mobility at alkaline pH. 
3.2. Biological activity 
Upon activation by factor Xa, in the presence of 
Ca 2* and phospholipids, prothrombin Metz generates 
in 60 rain < 4% of the clotting activity observed with 
normal prothrombin (fig.3A). 
However amidolytic activity on S22aa nd $216o 
(not shown) is generated (fig.3B) with an initial rate 
identical to that of normal prothrombin but reaching 
a plateau at 70% of the normal maximum activity. 
This at least shows that the factor Xa-catalyzed cleav- 
age, responsible for the unmasking of the active site, 
has occurred,leading to some form(s) of thrombin 
showing no activity toward fibrinogen and with 
modified catalytic properties toward small synthetic 
substrates. 
3.3. Cleavage pattern 
The cleavage pattern of prothrombin Metz by fac- 
tor Xa has been monitored by SDS-gel electropho- 
resis (fig.4). Two main abnormal features are observed. 
(1) Prethrombin 1 (P1) appears as for normal pro- 
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Fig.3. Generation of thrombin activity upon activation of 
prothrombin Metz (o-----~) and normal prothrombin (e =) 
by factor Xa (5 U/mg prothrombin) in the presence of Ca 2+ 
(2 mM) and phospholipids (40 t~g/mg prothrombin). (A) 
Clotting activity. (B) Amidolytic activity tan $2238 (Bz-Phe- 
Pip - Arg-p-nitroanilide). 
thrombin for short incubation times, but remains 
the major species at 120 min. 
(2) An abnormal intermediate with app. mol. wt 
25 000 is formed. 
The scanning of the gels clearly shows that in the 
case of normal prothrombin after 60 min incubation, 
P1 decreases concomitantly with an increase of pre. 
thrombin 2 whereas the amount of P1 remains con- 
stant for prothrombin Metz. These results how that 
the cleavage between F~ and PI occurs normally. 
Furthermore, this cleavage being catalyzed by throm- 
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Fig.4. Cleavage pattern of normal prothrombin and prothrombin Metz by factor Xa. The products of proteolysis have been ana- 
lysed by urea-SDS gel electrophoresis and their relative percentage measured by scanning of the gels. Prothrombin (II, l -); 
prethrombin 1 (PI =--a); prethrombin 2 (P2 e--o); fragment 1 (Fl 0-n); abnormal additional fragment 25 000 (o-.-.-o). 
All samples are unreduced. 
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bin, one may conclude that the abnormal form(s) of 
thrombin Metz still recognizes prothrombin as a sub- 
strate. The nature of the 25 000 mol. wt product is 
not clear at the present time. One possibility to be 
tested is to check if this abnormal intermediate might 
correspond to a degraded form of thrombin analogous 
to 0 thrombin with no clotting activity and a reduced 
activity on synthetic substrates. 
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